Last quarter (Q4 2023), Eyenovia's total revenue was $2.59K, an increase of Infinity% from the same quarter last year. In Q4, Eyenovia's net income was $-7.97M. See Eyenovia’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 3.79K	-	$ 14.00M	$ 2.00M	$ 0.00	$ 0.00
Cost of Revenue	$ 3.79K	-	$ -1.60M	$ 800.00K	$ 0.00	-
Gross Profit	-	-	$ 12.40M	$ 1.20M	$ 0.00	-
Operating Expense	$ 25.41M	$ 26.91M	$ -25.30M	$ 20.98M	$ 21.31M	$ 17.26M
Operating Income	$ -25.41M	$ -26.91M	$ -12.90M	$ -19.78M	$ -21.31M	$ -17.26M
Net Non Operating Interest Income Expense	$ -1.68M	$ -1.30M	$ -385.24K	$ 9.36K	$ 151.79K	$ 3.33K
Other Income Expense	$ 176.41K	$ -197.09K	$ -510.54K	-	-	-
Pretax Income	$ -27.26M	$ -28.01M	$ -12.78M	$ -19.77M	$ -21.16M	$ -17.25M
Tax Provision	$ -849.20K	$ -208.81K	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -27.26M	$ -28.01M	$ -12.78M	$ -19.77M	$ -21.16M	$ -17.25M
Basic EPS	$ -0.65	$ -0.83	$ -0.49	$ -0.94	$ -1.47	$ -1.82
Diluted EPS	$ -0.65	$ -0.83	$ -0.49	$ -0.94	$ -1.47	$ -1.82
Basic Average Shares	$ 164.13M	$ 33.65M	$ 26.32M	$ 21.05M	$ 14.35M	$ 9.48M
Diluted Average Shares	$ 164.13M	$ 33.65M	$ 26.32M	$ 21.05M	$ 14.35M	$ 9.48M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 25.41M	$ 26.91M	$ -26.90M	$ 21.78M	$ 21.31M	$ 17.26M
Net Income From Continuing And Discontinued Operation	$ -27.26M	$ -28.01M	$ -12.78M	$ -19.77M	$ -21.16M	$ -17.25M
Normalized Income	$ -19.52M	-	-	$ -19.77M	$ -21.16M	$ -17.25M
Interest Expense	-	-	-	$ 17.04K	$ 0.00	-
EBIT	$ -24.89M	$ -26.63M	$ -12.39M	$ -19.75M	$ -21.16M	$ -17.26M
EBITDA	$ -23.42M	$ -25.91M	$ -12.10M	$ -19.66M	$ -21.14M	$ -17.24M

Currency in USD

Eyenovia Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing